Literature DB >> 16640561

Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.

Alvaro Marín-Hernández1, Sara Rodríguez-Enríquez, Paola A Vital-González, Fanny L Flores-Rodríguez, Marina Macías-Silva, Marcela Sosa-Garrocho, Rafael Moreno-Sánchez.   

Abstract

Control analysis of the glycolytic flux was carried out in two fast-growth tumor cell types of human and rodent origin (HeLa and AS-30D, respectively). Determination of the maximal velocity (V(max)) of the 10 glycolytic enzymes from hexokinase to lactate dehydrogenase revealed that hexokinase (153-306 times) and phosphofructokinase-1 (PFK-1) (22-56 times) had higher over-expression in rat AS-30D hepatoma cells than in normal freshly isolated rat hepatocytes. Moreover, the steady-state concentrations of the glycolytic metabolites, particularly those of the products of hexokinase and PFK-1, were increased compared with hepatocytes. In HeLa cells, V(max) values and metabolite concentrations for the 10 glycolytic enzyme were also significantly increased, but to a much lesser extent (6-9 times for both hexokinase and PFK-1). Elasticity-based analysis of the glycolytic flux in AS-30D cells showed that the block of enzymes producing Fru(1,6)P2 (i.e. glucose transporter, hexokinase, hexosephosphate isomerase, PFK-1, and the Glc6P branches) exerted most of the flux control (70-75%), whereas the consuming block (from aldolase to lactate dehydrogenase) exhibited the remaining control. The Glc6P-producing block (glucose transporter and hexokinase) also showed high flux control (70%), which indicated low flux control by PFK-1. Kinetic analysis of PFK-1 showed low sensitivity towards its allosteric inhibitors citrate and ATP, at physiological concentrations of the activator Fru(2,6)P2. On the other hand, hexokinase activity was strongly inhibited by high, but physiological, concentrations of Glc6P. Therefore, the enhanced glycolytic flux in fast-growth tumor cells was still controlled by an over-produced, but Glc6P-inhibited hexokinase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640561     DOI: 10.1111/j.1742-4658.2006.05214.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  56 in total

1.  3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

2.  Comparative analysis of some aspects of mitochondrial metabolism in differentiated and undifferentiated neuroblastoma cells.

Authors:  Aleksandr Klepinin; Vladimir Chekulayev; Natalja Timohhina; Igor Shevchuk; Kersti Tepp; Andrus Kaldma; Andre Koit; Valdur Saks; Tuuli Kaambre
Journal:  J Bioenerg Biomembr       Date:  2013-09-27       Impact factor: 2.945

3.  What is the rate-limiting step towards aging? Chemical reaction kinetics might reconcile contradictory observations in experimental aging research.

Authors:  Sascha Kunath; Bernd Moosmann
Journal:  Geroscience       Date:  2019-02-27       Impact factor: 7.713

Review 4.  Control and regulation of pathways via negative feedback.

Authors:  Herbert M Sauro
Journal:  J R Soc Interface       Date:  2017-02       Impact factor: 4.118

Review 5.  Targeting glycogen metabolism in bladder cancer.

Authors:  Carolyn Ritterson Lew; Sunny Guin; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

6.  D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; K Yorita; S P Chung; D H Tran; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-07-17       Impact factor: 2.945

7.  Toward Defining the Pharmacophore for Positive Allosteric Modulation of PTH1 Receptor Signaling by Extracellular Nucleotides.

Authors:  Brandon H Kim; Fang I Wang; Alexey Pereverzev; Peter Chidiac; S Jeffrey Dixon
Journal:  ACS Pharmacol Transl Sci       Date:  2019-05-22

Review 8.  Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming.

Authors:  Lidia de Bari; Anna Atlante
Journal:  Cell Mol Life Sci       Date:  2018-05-04       Impact factor: 9.261

Review 9.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

10.  Evolution of allosteric citrate binding sites on 6-phosphofructo-1-kinase.

Authors:  Aleksandra Usenik; Matic Legiša
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.